Braeburn Pharmaceuticals Files For $150M IPO
Braeburn Pharmaceuticals Inc. — a pharmaceutical company set on commercializing its U.S. Food and Drug Administration-approved treatment for opioid addiction, which is a growing public health concern in the U.S. —...To view the full article, register now.
Already a subscriber? Click here to view full article